by Raynovich Rod | Jun 30, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Rayno Life Science Stocks Focused on Genetic Tests and Biomarkers We have been writing about molecular diagnostics and tools stocks for over 5 years. Here is the summary of our Portfolio. Yesterday we provided an update from BIO 2014 on personalized medicine and...
by Raynovich Rod | Jun 26, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
Challenges Ahead But Sequencing Is A Driver We first reported on Personalized Medicine in 2010 with an article on the importance of Biomarkers for exploiting breakthroughs in the molecular basis of disease. The BIO 2014 Personalized Medicine and Diagnostics Forum...
by Raynovich Rod | Jun 18, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update June 19.. 3:10 p EDT Ten Yr 2.62%, U.S.equities flat,biotech mixed, jobless claims down. Japanese and European equities up. Iraq on front page. GOLD Up $41 Breaks Through Resistance at $1300 Gold futures rose on technicals, Middle East turmoil, a weak dollar...
by Raynovich Rod | Jun 12, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
NASDAQ Off 0.8% On Disappointing Economic Data and Spiking Crude Islamic militants took major cities in Iraq causing a spike in oil to $106. The energy sector rallied 0.7% with many smaller players soaring over 4%. The energy sector is very strong up 10% YTD....
by Raynovich Rod | Jun 4, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Clinical Diagnostic Stocks Were Hit By Bio-Bubble or Revenue Miss Potential upside in EXAS, NSTG and NEOG all are Rayno Dx and Tools picks. With “momentum trading” days over for now, revenue growth is the focus. Companies with disappointing Q1 revenues:...
by Raynovich Rod | May 22, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Update 11/24/14 Clinical Diagnostics and Tools Stocks Review Performance YTD and compared to 11/13 YTD Top winners YTD are: EXAS 104%, ILMN 71.4%, ABAX 36.8% Top Losers YTD are: NSTG 16.6%, RGDX 54%, VRML 30.9% but all were good trades. IWM at $117.4 See Performance...
by Raynovich Rod | May 7, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Risk-Off -Stay With Large Caps In case you missed it the speculative frenzy in biotech stocks is over for now but there are always trading opportunities for the short and long term. We recently posted our Q1 Rayno Life Science update for biopharmaceuticals and the...
by Raynovich Rod | Apr 28, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Trinity Biotech (TRIB $24.90), a Buy Around $25 Barrons published an article over the weekend recommending Trinity Biotech plc, an Irish diagnostic Company focused in point of care (POC) and clinical laboratory diagnostic tests. We agree with the article and will...
by Raynovich Rod | Apr 25, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
Biotech Sector Perking Up in Active Trading 2:15 P Tuesday Key tracking indices: NASDAQ 4107 up 0.83%, IBB 229.2 up 2.75%, XBI 128.40 up 3.9%, XLV $58 up 0.55%. Rayno Biopharma Portfolio Movers Up: ABBV, ALKS, ALXN,BIIB, CBST, GILD, PCYC, SGEN etc Rayno Dx and...
by Raynovich Rod | Apr 3, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Caution As Life Science Stocks Are Consolidating Life science stocks had a wild roller coaster ride in 2014 with many stocks peaking around March 1. Momentum and cult stocks in our portfolio still had a good quarter with the following top winners: Illumina (ILMN) up...
